-
1.发明公开Method for cancer therapy with a parvovirus combined with chemotherapy 有权Krebstherapie mit einem Parvovirus in Kombination mit einer Chemotherapie
公开(公告)号：EP2082745A1
公开(公告)日：2009-07-29
申请号：EP07025216.8
申请日：2007-12-28
申请人： Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts , Ruprecht-Karls-Universität Heidelberg
发明人： Rommelaere, Jean , Raykov, Zahari , Schlehofer, Jörg , Kiprijanova, Irina , Heimberger, Tanja , Angelova, Assia , Geletneky, Karsten , Aprahamian, Marc
IPC分类号： A61K35/76 , A61K31/4188 , A61K31/7068 , A61P35/00
CPC分类号： A61K31/495 , A61K31/4188 , A61K31/7068 , A61K35/768 , C12N2750/14032 , A61K2300/00
摘要： Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.
摘要翻译： 描述了含有（a）细小病毒和（b）化学治疗剂的药物组合物，优选作为分开的实体。 细小病毒可能基于细小病毒H1，LuIII，小鼠微小病毒（MMV），小鼠细小病毒（MPV），大鼠微小病毒（RMV），大鼠细小病毒（RPV），大鼠病毒（RV），基于上述病毒物种的载体 ，和/或能够积极产生上述病毒物种的细胞。 该药物组合物有利于治疗肿瘤。 细小病毒或本发明的辅助物具有特殊用途的肿瘤包括神经胶质瘤，成神经管细胞瘤，脑膜瘤和胰腺癌。 优选的化学治疗剂是吉西他滨和替莫唑胺。
-
2.发明公开Use of parvovirus for eliminating cancer stem cells (CSCs) 审中-公开Verwendung vom Parvovirus zur Beseitigung von Krebsstammzellen
公开(公告)号：EP2404609A1
公开(公告)日：2012-01-11
申请号：EP10007007.7
申请日：2010-07-07
发明人： Rommelaere, Jean , Lacroix, Jeannine , Schlehofer, Jörg , Witt, Olaf , Deubzer, Hedwig , Kern, Sonja , Herold-Mende, Christel , Geletneky, Karsten , Leuchs, Barbara
IPC分类号： A61K35/76
CPC分类号： A61K35/768 , C12N2750/14332
摘要： Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
摘要翻译： 描述了细小病毒，优选H-1PV用于治疗性消除癌症干细胞（CSCs），优选神经母细胞瘤干细胞和成胶质细胞瘤干细胞的用途。
-
3.发明公开Method for cancer therapy based on co-administration of a parovirus and a cytokine 审中-公开基于细小病毒和细胞因子的同时给药用于癌症治疗的方法
公开(公告)号：EP2266588A1
公开(公告)日：2010-12-29
申请号：EP09007433.7
申请日：2009-06-04
申请人： Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts , Ruprecht-Karls-Universität Heidelberg
发明人： Kiprijanova, Irina , Fischer, Manuel , Rommelaere, Jean , Schlehofer, Jörg , Geletneky, Karsten
CPC分类号： A61K35/768 , A61K38/217 , C12N7/00 , C12N2750/14332 , C12N2750/14333 , C12N2750/14371 , A61K2300/00
摘要： Desribed is a pharmaceutical composition comprising (a) a parvovirus and (b) a cytokine, preferably IFN-γ, and the use of said composition for treatment of cancer, e.g., a brain tumor.
摘要翻译： Desribed是包含（A）细小病毒和（b）的细胞因子，优选IFN-³，和用于治疗癌症，E. G.，脑肿瘤中使用所述组合物的药物组合物。
-
公开(公告)号：EP2431045B1
公开(公告)日：2013-03-06
申请号：EP11003657.1
申请日：2008-12-23
发明人： Rommelaere, Jean , Raykov, Zahari , Schlehofer, Jörg , Kiprijanova, Irina , Heimberger, Tanja , Angelova, Assia , Geletneky, Karsten , Aprahamian, Marc
IPC分类号： A61K35/76 , A61K31/4188 , A61K31/7068 , A61P35/00
CPC分类号： A61K31/495 , A61K31/4188 , A61K31/7068 , A61K35/768 , C12N2750/14032 , A61K2300/00
摘要： Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.
-
公开(公告)号：EP2082745B1
公开(公告)日：2012-12-19
申请号：EP07025216.8
申请日：2007-12-28
申请人： Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts , Ruprecht-Karls-Universität Heidelberg
发明人： Rommelaere, Jean , Raykov, Zahari , Schlehofer, Jörg , Kiprijanova, Irina , Heimberger, Tanja , Angelova, Assia , Geletneky, Karsten , Aprahamian, Marc
IPC分类号： A61K35/76 , A61K31/4188 , A61K31/7068 , A61P35/00
CPC分类号： A61K31/495 , A61K31/4188 , A61K31/7068 , A61K35/768 , C12N2750/14032 , A61K2300/00
摘要： Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.
-
公开(公告)号：EP2431045A1
公开(公告)日：2012-03-21
申请号：EP11003657.1
申请日：2008-12-23
发明人： Rommelaere, Jean , Raykov, Zahari , Schlehofer, Jörg , Kiprijanova, Irina , Heimberger, Tanja , Angelova, Assia , Geletneky, Karsten , Aprahamian, Marc
IPC分类号： A61K35/76 , A61K31/4188 , A61K31/7068 , A61P35/00
CPC分类号： A61K31/495 , A61K31/4188 , A61K31/7068 , A61K35/768 , C12N2750/14032 , A61K2300/00
摘要： Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of pancreatic cancer.
摘要翻译： 描述了含有（a）细小病毒和（b）化学治疗剂的药物组合物，优选作为分开的实体。 细小病毒可能基于细小病毒H1，LuIII，小鼠微小病毒（MMV），小鼠细小病毒（MPV），大鼠微小病毒（RMV），大鼠细小病毒（RPV），大鼠病毒（RV），基于上述病毒物种的载体 ，和/或能够积极产生上述病毒物种的细胞。 该药物组合物有利于胰腺癌的治疗。
-
7.发明公开Parvovirus for treatment of tumours by intranasal application 审中-公开细小病毒zur Behandlung von Tumoren手套内裤Anwendung
公开(公告)号：EP2397146A1
公开(公告)日：2011-12-21
申请号：EP10006082.1
申请日：2010-06-11
发明人： Rommelaere, Jean , Kiprijanova, Irina , Schlehofer, Jörg , Ayache, Ali , Fischer, Manuel , Thomas, Nadja
CPC分类号： A61K35/768 , A61K2039/543 , C12N2750/14332
摘要： Described is the use of an oncolytic parvovirus for the manufacture of a medicament for the treatment of a tumor and/or tumor metastases, in particular a brain tumor, by intranasal administration. A preferred parvovirus is H1-PV. Intranasal parvotherapy can improve the prognosis of said tumors. Parvovirus H1 infection leads to killing of tumor cells but does not harm normal brain cells. Thus, the intranasal use of a parvovirus like H1, a related virus or vectors based on such viruses offers the chance of tumor specific therapy without severe neurological side effects.
摘要翻译： 描述了溶瘤细小病毒在制备用于通过鼻内给药治疗肿瘤和/或肿瘤转移，特别是脑肿瘤的药物中的用途。 优选的细小病毒是H1-PV。 鼻内治疗可以改善所述肿瘤的预后。 细小病毒H1感染导致肿瘤细胞死亡，但不会损害正常的脑细胞。 因此，鼻内使用细胞病毒如H1，相关病毒或基于这种病毒的载体提供了肿瘤特异性治疗的机会，而没有严重的神经系统副作用。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.014 秒)
